A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Agitation in Participants With Alzheimer's Disease (BALANCE-AAD-1)
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Agitation in Participants With Alzheimer's Disease (BALANCE-AAD-1)
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
Inclusion Criteria
Exclusion Criteria
Clinical.Trials@bms.com855-907-3286
Huntsville, Alabama 35801, United States
Philadelphia, Pennsylvania 19107, United States
Ciudad Autónoma de Buenos Aires, Buenos Aires C1060AAE, Argentina
Shanghai Shi, Shanghai Municipality 200030, China
256-551-4512
909-488-9116
214-893-0542
858-246-1303
714-717-6039
562-548-8500
714-999-6688
303-724-2046
202-687-3350
386-278-8000
717-357-1569
352-775-1000
404-537-1281
912-744-0800
401-435-8950
406-543-9700
402-937-9293
281-630-2316
516-562-3492
845-674-9398
315-529-0766
980-209-9784
919-784-1092
216-403-6847
215-503-2823
901-866-9252
601-594-0792
817-602-5188
949-491-0710
505-903-1715
214-407-8640
000-000-0000
385-392-2200